tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
PTC Therapeutics price target lowered to $71 from $76 at Morgan Stanley
PremiumThe FlyPTC Therapeutics price target lowered to $71 from $76 at Morgan Stanley
1M ago
PTC Therapeutics: Buy Rating Affirmed Amid Temporary Weakness and Promising Pipeline
Premium
Ratings
PTC Therapeutics: Buy Rating Affirmed Amid Temporary Weakness and Promising Pipeline
1M ago
JPMorgan adds PTC Therapeutics to Analyst Focus List after selloff
Premium
The Fly
JPMorgan adds PTC Therapeutics to Analyst Focus List after selloff
1M ago
PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital
PremiumThe FlyPTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital
1M ago
PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback
Premium
Ratings
PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback
1M ago
PTC Therapeutics price target lowered to $50 from $56 at TD Cowen
Premium
The Fly
PTC Therapeutics price target lowered to $50 from $56 at TD Cowen
1M ago
PTC Therapeutics price target lowered to $70 from $72 at Baird
PremiumThe FlyPTC Therapeutics price target lowered to $70 from $72 at Baird
2M ago
PTC Therapeutics price target raised to $56 from $52 at TD Cowen
Premium
The Fly
PTC Therapeutics price target raised to $56 from $52 at TD Cowen
2M ago
PTC Therapeutics price target raised to $63 from $60 at RBC Capital
Premium
The Fly
PTC Therapeutics price target raised to $63 from $60 at RBC Capital
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100